TOVX

5.33% 0.0113

Pre-mercato: .22 -0.0032 -1.43%

Theriva Biologics Inc (TOVX)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Theriva Biologics Inc Stock (TOVX) Company Profile

Theriva Biologics Inc

Healthcare (1114)

Biotechnology (623)

301 417 4364

9605 Medical Center Drive, Suite 270, Rockville

Prossima data di guadagno

Ultimi documenti SEC

TOVX's Discussions on Twitter

Compare TOVX vs VRTX, REGN, ALNY, ARGX, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TOVX Theriva Biologics Inc	0.2232	9.72M	0	-23.74M	-16.70M	-4.0366
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Theriva Biologics Inc Borsa (TOVX) Ultime notizie

Theriva Biologics Inc Azioni (TOVX) Dati Finanziari

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc Stock (TOVX) Company Profile

Compare TOVX vs VRTX, REGN, ALNY, ARGX, INSM

Theriva Biologics Inc Borsa (TOVX) Ultime notizie

Portfolio Recap: Does Theriva Biologics Inc have strong EBITDA margins2026 Movers & Weekly Top Gainers Trade List - baoquankhu1.vn

Maxim Group Maintains Theriva Biologics(TOVX.US) With Hold Rating - Moomoo

Maxim Group Maintains Theriva Biologics(TOVX.US) With Hold Rating, Announces Target Price $0.22 - Moomoo

Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA - TipRanks

Theriva Biologics Receives FDA Agreement to Advance VCN-01 to Phase 3 Trial for Metastatic Pancreatic Cancer 1 - Minichart

Theriva Biologics Announces Positive End-Of-Phase 2 Meeting With U.S. FDA Regarding The Design Of A Phase 3 Trial Of VCN-01 In Metastatic Pancreatic Ductal Adenocarcinoma - marketscreener.com

Theriva™ Biologics reports full-year 2025 operational highlights and financial results - MSN

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Stocktwits

Theriva Biologics (TOVX) Advances Phase 3 Clinical Trial Plans f - GuruFocus

Theriva Biologics Advances VCN-01 Into Pivotal Phase 3 - TipRanks

Theriva gets FDA alignment on phase 3 trial design for VCN-01 - Investing.com Canada

Theriva Biologics aligns with FDA on Phase 3 VCN-01 design for metastatic PDAC - TradingView

Theriva Biologics (NYSE: TOVX) gains FDA alignment on pivotal VCN-01 Phase 3 in metastatic PDAC - Stock Titan

Theriva pushes pancreatic cancer drug VCN-01 toward Phase 3 - Stock Titan

If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX) - Stock Titan

Theriva Biologics (TOVX) Registration Filing Summary - Quartr

Chart Watch: Is Theriva Biologics Inc showing insider buying2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn

TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill

Aug Swings: Will Theriva Biologics Inc outperform its industry peers2026 Key Lessons & Risk Managed Investment Signals - baoquankhu1.vn

Theriva Biologics (NYSE: TOVX) puts 16.2M warrant share issuance to vote - Stock Titan

Theriva Biologics, Inc. (TOVX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Bitget

TOVX Reports Strong Cash Position and Funding Plans for Clinical Trials - GuruFocus

Theriva 10-K: Net loss $23.74M, EPS $(2.08); Operating loss $24.05M - TradingView

Theriva Biologics reports $13.1M year-end cash, $25.2M net loss for 2025 - TradingView

Form 10-K Theriva Biologics, Inc. For: Dec 31 - StreetInsider

Theriva Biologics (NYSE: TOVX) details 2025 loss and cash runway into 2027 - Stock Titan

Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan

TOVX Advances Oncology Pipeline with Strategic Licensing and Cli - GuruFocus

Theriva Biologics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Aug Mood: Can Theriva Biologics Inc maintain sales growthStock Surge & Fast Entry Momentum Trade Alerts - baoquankhu1.vn

Aug Shorts: Can Theriva Biologics Inc maintain sales growthAnalyst Upgrade & Step-by-Step Trade Execution Guides - baoquankhu1.vn

Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 - Stocktwits

TOVX Should I Buy - Intellectia AI

TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Stocktwits

TOVX Technical Analysis & ETF Price Forecast - Intellectia AI

Is Theriva Biologics Inc. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru

TOVX Theriva Biologics AMEX pre-market +12% Feb 20 2026: Most active - Meyka

$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum - GlobeNewswire Inc.

Aug Update: What are Theriva Biologics Incs technical support levelsJuly 2025 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn

Theriva Biologics licenses Syn-020 to Rasayana Therapeutics for multiple indications - marketscreener.com

Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications - TradingView

Theriva Biologics (TOVX) Licenses SYN-020 to Rasayana Therapeuti - GuruFocus

Theriva Licenses SYN-020, Refocuses on Cancer Pipeline - TipRanks

Theriva Biologics Inc (referred to as Theriva Biologics) has successfully received a $300,000 upfront payment at the time of signing the agreement. - Bitget

Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Bitget

How Theriva Biologics Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Daily Price Action Insights - mfd.ru

Published on: 2026-02-14 06:14:36 - mfd.ru

Theriva Biologics Faces Delay in Warrant Approval Meeting - The Globe and Mail

Theriva Biologics Inc Azioni (TOVX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a TOVX